BPMC - Blueprint Medicines: Rampant Growth Mostly Priced In
2024-05-04 07:43:58 ET
Summary
- Blueprint Medicines generates growing revenues from its FDA-approved product AYVAKIT/AYVAKYT.
- AYVAKIT has been approved for multiple indications, including gastrointestinal stromal tumor and systemic mastocytosis.
- Blueprint reported strong Q1 2024 earnings, achieving $92.5 million in AYVAKIT net product revenues and raising guidance for full-year revenues.
This is my initial Blueprint Medicines ( BPMC ) article. Blueprint is a commercial stage biotech which is pegging potential blockbuster revenues for AYVAKIT/AYVAKYT (avapritinib), its one FDA approved product....
Blueprint Medicines: Rampant Growth Mostly Priced In